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tradictory and variable except a few important issues. From the
perspective of clinical health care delivery, therapeutic noncom-
pliance remains a major problem in enhancing health care 
outcomes.
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OBJECTIVES: A new utility index derived of the SF-36, the SF-
6D, was recently developed and has generated an increasing
research in different groups of patients and has also been com-
pared with other utility measures, as it is the EQ-5D. The
purpose of present work was to evaluate the differences between
the weighted and not weighted version of two utility measures:
the Spanish SF-6D and EQ-5D. METHODS: A total of 1843
complete measures of the SF-36 and the EQ-5D (5 items and
visual analogic scale-VAS) from 1283 patients who received a
solid organ transplant (kidney, liver, heart or lung) were used.
Data were collected at different moments during the ﬁrst year
after the surgery in the context of the Spanish Research Network
on Transplantation. SF-6D values were calculated using the
model proposed by its creator (weighted version) and without
tariff values, as has been proposed by some authors (not
weighted). EQ-5D values were calculated using Spanish VAS
tariff (VAS-t), the time-trade off tariff (TTO-t) and also without
tariff values (not weighted). Spearman correlation coefﬁcients
were calculated between SF-6D (weighted and not weighted) and
EQ-5D values (VAS-t, TTO-t and not weighted). RESULTS:
Mean value of weighted SF-6D was 0.67 (0.15) and not
weighted, 0.72 (0.15). Mean values of EQ-5D VAS-t was 0.69
(0.24), of TTO-t, 0.70 (0.32) and of not weighted EQ-5D, 0.63
(0.33). SF-6D values had moderate correlation with EQ-5D VAS-
t (r = 0.734) and EQ-5D TTO-t (r = 0.731) (both p < 0.001).
Using the SF-6D index without tariff values, it had a high cor-
relation with the weighted version of SF-6D (r = 0.969, p <
0.001), and moderate with the EQ-5D VAS-t (r = 0.754), EQ-
5D TTO-t (r = 0.750) and no weighted EQ-5D (r = 0.784) (p <
0.001). CONCLUSIONS: The efforts made to get the prefer-
ences values and calculate the weights in utility indexes do not
seem to add enough information to make them worthy.
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OBJECTIVES: It is well recognised that electronic data capture
(EDC) is revolutionising the data collection and management of
clinical trials data especially for pre-registration Phase I to III
studies. We will discuss the beneﬁts of the use of EDC for patient
reported outcomes and especially within the context of large
observational studies. METHODS: Using EDC, patient reported
outcome data are collected directly by the patient onto the data
capture device; this can be either a tablet pc at the study site or
using a PDA for diary data. Whilst the patient is entering data,
the device will prompt them if they do not ﬁll in the question-
naire correctly or do not complete particular questions.
RESULTS: Even this simple interaction with the patient of ensur-
ing the answer provided is the most appropriate one improves
the quality of the patient reported outcome data. For example,
the query rate for these data is usually reduced from 6 to 10 fold
compared with paper CRF collection and of course for patient
reported data these queries usually cannot be updated so that
these data remain inconsistent and of poorer quality. Other ben-
eﬁts include the on-line reporting of data which is especially ben-
eﬁcial for observational studies of moderate to long duration.
Often several statistical reports are made from these data for
example by conducting interims for baseline data, 3-month, 6-
month, and 1-year data, etc. These reports were often produced
several months after the last data were collected due to the delay
between data processing of paper CRF data and the processes
involve with statistical reporting. CONCLUSIONS: Now it is
possible to provide near real-time access to reports via EDC
working with a suite of pre-validated statistical programs. These
can be produced on an on-going basis, for example we can
update our reports daily.
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OBJECTIVE: Conduct a systematic review of the literature on
delayed-action dose preparation compared to regular dose
preparation, and to examine the impact of a change in dose fre-
quency on compliance and health outcomes (e.g., health-related
quality of life, patient satisfaction, treatment costs), as well 
as efﬁcacy and tolerability proﬁle. METHODS: The medical lit-
erature databases MEDLINE and Cochrane Library were
reviewed from 1966 through 2006 for published, peer-reviewed
articles. Search terms were combinations of “delayed-action
preparations”, “dose frequency”, “dose administration sched-
ule”, “dosing” and “efﬁcacy”, “safety”, “clinical effectiveness”,
“preferences”, “adherence”, “compliance”, “persistence”,
“health-related quality of life”, “patient satisfaction”, “resource
use”, and “costs”. References from identiﬁed articles were not
used to expand the search. Two reviewers independently
reviewed titles, abstracts, and ﬁnally full-text articles. A total of
57 peer-review articles were selected for the full-text review,
including 14 literature/systematic reviews and 2 meta-analysis
articles. RESULTS: All of the clinical studies, except 2, support
better or comparable efﬁcacy when using a simple dose (e.g.,
weekly dose vs. multiple doses per week or once-daily versus
twice-daily or three-times-daily) to treat clinical symptoms in the
following disease areas: cardiovascular disorders, diabetes, neu-
rological/psychological disorders, rheumatoid/muscle disorders,
nephrology/urology disorders. Along with literature/systematic
reviews and meta-analysis articles, these studies have supported
the general advantages of reducing dosing frequency on
improved compliance (16 studies), improved quality of life or
patient satisfaction (8 studies), greater control over side effects
(3 studies), and improved economic outcomes using extended-
release formulation (2 studies). CONCLUSION: In general,
reducing dose frequency by using a delayed-action dose may
offer beneﬁts for patients in terms of improving medication com-
pliance, effectiveness and adverse effect proﬁles, while possibly
reducing health care costs. However, physicians and patients
need to bear in mind that the wide variety of delivery systems
are available to ﬁnd the most appropriate one for a particular
patient.
